JOHNSON & JOHNSON

ISIN: US4781601046 WKN: 478160104 Asset Class: Stock



Company Profile

Non-current liabilities

Different income Other liabilities

Total assets

Ralanco notos

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Financial figures, Fiscal year: from 01.01. to 31.12. 2023 2022 2021 **Financial figures** Assets Liabilities and equity Assets Liabilities and equity Assets Liabilities and equity **Current assets** 53,495,000,000 55,294,000,000 60,979,000,000 Common stock capital 3,120,000,000 3,120,000,000 3,120,000,000 **Fixed assets** 114,063,000,000 132,084,000,000 121,039,000,000 Equity capital of a company 68.774.000.000 76.804.000.000 74.023.000.000 21.859.000.000 14.127.000.000 14.487.000.000 Cash and cash equivalents Accrued liabilities 7.149.000.000 6.767.000.000 8.898.000.000 Other assets **Current liabilities** 46,282,000,000 55,802,000,000 45,226,000,000 Prepayments and accrued income

52,502,000,000

15,179,000,000

167,558,000,000

187,378,000,000

167,558,000,000

54,772,000,000

13 443 000 000

187,378,000,000

182,018,000,000

Datatice flotes			
	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	131,900	152,700	141,700
Equity ratio	41.04%	40.99%	40.67%
Debt-equity ratio	143.64%	143.97%	145.89%

Others			
	2023	2022	2021
Tax Expense Rate	11.53%	17.42%	8.33%

62,769,000,000

15,399,000,000

182,018,000,000

JOHNSON & JOHNSON

ISIN: US4781601046 WKN: 478160104 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	85,152,000,000	95,015,000,000	93,758,000,000
Net income	13,326,000,000	17,941,000,000	20,878,000,000
EBIT	13,820,083,200	20,319,600,000	21,610,870,400
Operating income before taxes	15,062,000,000	21,725,000,000	22,776,000,000
Cash Flow	22,791,000,000	21,194,000,000	23,410,000,000
Net interest income	14,000,000	-400,000,000	-755,000,000
Research and development expenses	15,048,000,000	14,752,000,000	14,744,000,000
Income taxes	1,736,000,000	3,784,000,000	1,898,000,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	592,901	571,459	607,674

Board of Directors

Members of Management Board		
Jennifer Doudna	Member of Board of Directors	
Mark McClellan	Member of Board of Directors	
Mary Beckerle	Member of Board of Directors	
Nadja West	Member of Board of Directors	
Paula Johnson	Member of Board of Directors	
Anne Mulcahy	Member of Board of Directors	
D. Davis	Member of Board of Directors	
Darius Adamczyk	Member of Board of Directors	
Eugene Woods	Member of Board of Directors	
Hubert Joly	Member of Board of Directors	
Marillyn Hewson	Member of Board of Directors	
Mark Weinberger	Member of Board of Directors	
Joaquin Duato	Chairman of Managing Board	
James Swanson	Member of Executive Committee	
Jennifer Taubert	Member of Executive Committee	
Joseph J. Wolk	Member of Executive Committee	
Kathy Wengel	Member of Executive Committee	
Liz Forminard	Member of Executive Committee	
Peter M. Fasolo	Member of Executive Committee	
Vanessa Broadhurst	Member of Executive Committee	
William N. Hait	Member of Executive Committee	